Degradable co-delivery nanoplatforms for inflammation-targeted therapy against atherosclerosis

The study developed an inflammation-targeted nanoplatform using IL-1Ra-loaded copper-doped mesoporous silica nanoparticles ([email protected]) for treating atherosclerosis. This nanoplatform co-delivered IL-1Ra and copper ions, addressing limitations like liver damage and short in vivo half-life associated with traditional therapies. The [email protected] demonstrated high drug-loading efficiency, sustained release, and biodegradability. Copper ions induced macrophage apoptosis through ROS production, while IL-1Ra provided anti-inflammatory effects. In vivo results showed significant reductions in arterial stenosis, plaque burden, and macrophage infiltration, highlighting the potential of this novel strategy for inflammation-targeted therapy against atherosclerosis.